Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$23.2MBeat by $15.4M
EPS-$0.15Beat by $0.23
Revenue estimate$7.8M
EPS estimate-$0.38

Next report

Nov 5, 2026 (in a month)
Revenue estimate$31.5M
EPS estimate-$0.24

Financials

Q2 2025

Income statement

See full
Revenue$23.2M+394%
Operating income-$15.6M+52.3%
Net income-$12.3M+59.4%
EPS (diluted)-$0.15+65.1%

Balance sheet

See full
Cash & equivalents$69.4M-36.2%
Total debt$41.1M-7.3%
Total equity$268.1M+19.3%
Total assets$359.6M+4.5%

Cash flow

See full
Operating cash flow-$34.7M-25.0%
CapEx$1.7M-16.2%
Free cash flow-$36.4M-22.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$291.56M+9.4%
Enterprise value$263.26M+30.4%
P/S1.6×-44.6×

Profitability

See full
FCF margin13.4%—

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio7.2×+0.6×

FAQ

When did Monte Rosa Therapeutics, Inc. report Q2 2025 earnings?
Monte Rosa Therapeutics, Inc. (GLUE) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Monte Rosa Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Monte Rosa Therapeutics, Inc. reported revenue of $23.2M and eps of $-0.15 for Q2 2025.
Did Monte Rosa Therapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $7.8M by $15.4M. EPS beat the consensus estimate of $-0.38 by $0.23.
How did Monte Rosa Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 394.0% from $4.7M a year earlier and eps grew 65.1% from $-0.43.
Where can I find Monte Rosa Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-104545) and the 10-Q periodic report (0000950170-25-104550) directly on SEC EDGAR. The filing index links above go to sec.gov.